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Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) is a cytokine of the TNF superfamily that activates
the Fn14 receptor. TWEAK may regulate cell proliferation, cell
death, cell differentiation, and inflammation. TWEAK and
Fn14 are constitutively present in the kidney. Sources of
TWEAK and Fn14 include intrinsic renal cells and infiltrating
leukocytes. Basal Fn14 expression is low, but Fn14 is greatly
upregulated during kidney injury. TWEAK contributes to
kidney inflammation promoting chemokine secretion by
renal cells through canonical and non-canonical NFjB
activation. TWEAK also promotes tubular cell proliferation.
However, TWEAK induces mesangial and tubular cell
apoptosis under proinflammatory conditions. These data
indicate that TWEAK is a multifunctional cytokine in the
kidney, the actions of which are modulated by the cell
microenvironment. Confirmation of the role of TWEAK in
kidney injury came from functional studies in experimental
animal models. The TWEAK/Fn14 pathway contributed to
cell death and interstitial inflammation during acute
kidney injury, to glomerular injury in lupus nephritis,
to hyperlipidemia-associated kidney injury, and to tubular
cell hyperplasia following unilateral nephrectomy. Circulating
soluble TWEAK (sTWEAK) levels are a potential biomarker of
adverse outcomes in chronic kidney disease and urinary
sTWEAK is a potential biomarker of lupus nephritis activity.
The available evidence suggests that TWEAK may provide
diagnostic information and be a therapeutic target in renal
injury. Its role in human kidney disease should be further
explored.
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TWEAK AND Fn14
Tumor necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK, Apo3L, TNFSF12) is a member of the TNF
superfamily (TNFSF).1 Members of the TNFSF are widely
expressed and have important roles in immune responses,
inflammation, cell homeostasis, and tissue repair.2,3 TNFSF
members are type II transmembrane proteins that, in some
cases, can be processed into smaller, secreted proteins with
biological activity.4,5 TNFSF cytokines contain a C-terminal
TNF homology domain that mediates self-trimerization and
receptor binding. Each ligand binds to one or more members
of the TNF receptor superfamily (TNFRSF).4,5 TNFRSF
receptors have an extracellular domain with a ligand-binding
region and a cytoplasmic tail with one or more adaptor
protein-binding sites, which activate signal cascades.
The human TWEAK gene encodes a type II transmem-
brane glycoprotein of 249 amino acids (aa). The C-terminal
extracellular domain (206-aa) contains the receptor-binding
site and a potential N-glycosylation site.1 This domain is
proteolytically processed, probably, at one or both of two
furin consensus cleavage sites.1,6 The result from this proteo-
lysis is a 156-aa-soluble TWEAK isoform (sTWEAK).1,7,8 The
N-terminal intracellular domain (18-aa) contains a potential
protein kinase C phosphorylation site and several nuclear
localization sequences.1,9–11 TWEAK may localize to the
nuclei,11 but the biological significance is unknown. Cells can
express both full-length mTWEAK (membrane-anchored
TWEAK) and sTWEAK.6,7 The intracellular domain of
TWEAK contains a furin recognition site, suggesting that
full-length TWEAK can be cleaved intracellularly.6 Both
sTWEAK and mTWEAK bind and activate fibroblast growth
factor-inducible-14 (Fn14, TWEAK receptor, TNFRSF12A,
CD266)6,12 (Figure 1).
Initial reports of TWEAK binding to DR3 (Apo3/
TRAMP),9 a TNFRSF member, were not confirmed.7,13,14
In 2001, Fn14 was found to be the TWEAK receptor.15,16
Fn14 had been described in fibroblasts as a growth factor-
regulated, immediate-early response gene.17 The human
Fn14 gene encodes a type I transmembrane protein of 129-
aa, which is processed into a mature 102-aa protein. Fn14 is
the smallest member of TNFRSF. The extracellular domain
(53-aa) contains a cystein-rich domain necessary for TWEAK
binding.18,19 The intracellular domain (29-aa) does not
contain a death domain, thus differing from many TNFRSF
members, but contains TNFR-associated factor-binding sites.18
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TWEAK is the only TNFSF member that binds Fn14.
There is unconfirmed evidence of the existence of a second
TWEAK signaling-transducing receptor. TWEAK induced
signal transduction in monocytes/macrophages lacking
Fn14.20 In addition, CD163 from monocytes lacking Fn14
can also bind TWEAK.21 CD163 could be a TWEAK scavenger,
as no TWEAK-induced signaling through CD163 has been
observed.21,22
TWEAK has multiple functions with potential physio-
pathological relevance that depend on the microenviron-
ment, the cell type, and the cell state of activation (Figure 2).
The basis for these differential responses is poorly under-
stood. TWEAK can regulate cell proliferation, cell death,
cell migration, cell differentiation, tissue regeneration,
neo-angiogenesis, and inflammation.23–32 Fn14 expression is
strongly induced during tissue injury, repair, and remodeling,
whereas changes in TWEAK expression are milder.16,33,34
TWEAK has a role in injury of different organs, including
the central nervous system, liver, gut, the vasculature, skeletal
muscle, heart, and kidney.29,34–39 However, the precise role of
TWEAK in different diseases requires refined characteri-
zation, as it may be potentially deleterious or beneficial
depending on the context and stage of the disease.8,40 We will
review the role of TWEAK/Fn14 in kidney disease.
REGULATION OF TWEAK/Fn14 EXPRESSION IN RENAL CELLS
TWEAK, in contrast to other TNFSF cytokines, is broadly
expressed and can be found at high levels in the pancreas,
intestine, heart, brain, lung, ovary, vasculature, and skeletal
muscle, and at lower levels in the liver and kidney.1,9
However, the precise cellular sources of circulating sTWEAK
are unclear. Fn14 is expressed by many cell types, including
epithelial, mesenchymal, and endothelial cells.40 Fn14
expression in healthy tissues, including the kidneys, is usually
low, but it is rapidly and highly upregulated in response to
injury.15,16,23,29,33–36,41–45
Both TWEAK and Fn14 are constitutively expressed at
low levels in normal kidneys. Potential local sources of kidney
TWEAK include infiltrating monocytes/macrophages and
T lymphocytes, and resident cells such as tubular and
mesangial cells.7,14,33,46,47 Low-level constitutive Fn14 expres-
sion is observed in tubular cells, mesangial cells, and podocytes
and these cells respond to TWEAK stimulation in culture.33,48
TWEAK and Fn14 are constitutively expressed in murine
and human renal tubular cells. Basal Fn14 protein levels are
low but proinflammatory cytokines quickly (within 2 h) and
transitorily increased Fn14 expression.33 The early Fn14
induction in tubular cells is consistent with reports in other
cell types.17,49 Growth factors present in serum also increase
Fn14 expression in tubular cells in a more sustained
manner.45 Growth factors also upregulate Fn14 in endothelial
cells.50 The molecular mechanisms that regulate Fn14
expression are not well defined. The Rho/ROCK pathway
has been implicated in Fn14 upregulation in human aortic
smooth muscle cells and in cardiomyocytes.49,51 TWEAK
expression is upregulated in cultured tubular cells by growth
factors from serum.45 It is conceivable that these same
factors contribute to constitutive TWEAK or Fn14 expression
in vivo. Podocytes and mesangial cells constitutively express
TWEAK and Fn14,48,52 (unpublished observation). However,
the regulation of TWEAK and Fn14 expression in podocytes
and mesangial cells has not been studied.
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Figure 1 |Basic biology of the TWEAK/Fn14 system. (a) TWEAK is a type II transmembrane glycoprotein that may be proteolytically
processed, yielding soluble TWEAK (sTWEAK). Both bind to and activate the TWEAK receptor (TWEAKR), Fn14. In addition, the N-terminal
intracellular domain may be cleaved and contains nuclear localization sequences (NLSs). The functional consequences of this are unclear.
Fn14 is a type I transmembrane protein belonging to the TNF receptor superfamily that lacks a death domain (DD) but contains
a TRAF-binding domain (TRAF BD). (b) Fn14 is rapidly and strongly upregulated upon tissue injury. Trimerization of the receptor upon
TWEAK binding transduces intracellular signaling. TWEAK may also bind to the CD163 scavenger receptor in macrophages. The biological
significance of this interaction requires further studies. F, furin cleavage site; mTWEAK, membrane-anchored TWEAK; TNF, tumor necrosis
factor; TRAF, TNF receptor-associated factor.
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TWEAK ACTIONS ON RENAL CELLS
A series of reports have highlighted the actions of TWEAK
in renal tubular cells, mesangial cells, and podocytes. The
identification of signal transduction pathways activated by
TWEAK in renal cells is critical to understanding the role of
this cytokine in kidney disease (Table 1, Figure 2).
Proinflammatory actions
The proinflammatory effect of TWEAK has been studied
in detail in renal tubular cells. Tubular cells compose most
of the mass of the kidneys and synthesize cytokines,
chemokines, and adhesion molecules, which promote inter-
stitial infiltration by inflammatory cells.53,54 The transcrip-
tion factor nuclear factor-kB (NFkB) has a key role in the
inflammatory response of tubular cells.55 In quiescent cells,
inactive NFkB proteins are present in the cytoplasm bound to
inhibitor subunits (IkBs). When NFkB signaling is activated,
IkB proteins are phosphorylated and degraded, thus releasing
NFkB, which migrates to the nucleus, binds to DNA, and
activates or represses gene transcription. There are, at least,
two different NFkB activation pathways, the canonical or
classical and the non-canonical or alternative.55 Each path-
way may activate a different set of genes. TWEAK engage-
ment of Fn14 activates the canonical NFkB pathway in
tubular epithelial cells56 (Figure 3). Thus, TWEAK induces an
early (from 30min), parthenolide-sensitive nuclear trans-
location and DNA binding of RelA-containing complexes,
leading to gene expression and secretion of monocyte
chemoattractant protein 1, interleukin (IL)-6, and RANTES.56,57
In vivo, this leads to interstitial macrophage infiltration of
normal kidneys.56 In addition, TWEAK can activate the non-
canonical NFkB pathway (RelB/NFeˆB2).58 In this regard,
TWEAK induces non-canonical NFkB activation in tubular
epithelial cells (Figure 3), whereas TNFa does not, suggesting
that TWEAK and TNFa are not redundant cytokines in renal
injury.57 TWEAK-induced non-canonical NFkB activation is
delayed (peaking at 6–24h) compared with canonical NFkB
activation. As a consequence of non-canonical NFkB activation,
TWEAK induces the delayed (peaking at 24h) expression of
CCL21 and CCL19,57 and CCL21 could contribute to
recruitment T cells and fibrocytes to the kidney.59 TWEAK is
synergistic with oxidized low-density lipoprotein in promoting
inflammatory gene expression in tubular cells.37
TWEAK also induces the expression of inflammatory
mediators in mesangial cells and podocytes, and this effect is
also mediated by NFeˆB.48,52 TWEAK activates the mitogen-
activated protein kinases (MAPKs) extracellular signal-
regulated kinase, Jun N-terminal kinase, and p38, as well as
phosphoinositide 3-kinase/Akt in different cell types, includ-
ing renal cells.42,45,48,50,60,61 In this regard, MAPKs are
involved in regulating chemokine production by mesangial
cells and podocytes.48
The kidney proinflammatory effect of TWEAK is observed
in vivo. Systemic TWEAK administration induces canonical
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Figure 2 |Microenvironment-dependent actions of TWEAK
on renal tubular cells. TWEAK activates the Fn14 receptor in
renal tubular cells. The consequences of Fn14 activation differ
depending on the microenvironment. Growth factors increase
TWEAK and Fn14 expression and may increase BclxL and decrease
Bax. Growth factors increase the proliferative effect of TWEAK
on the tubular epithelium. The canonical activation of NFkB
and activation of MAPK contribute to the proliferative effect of
TWEAK. In contrast, in an inflammatory environment (for example,
in the presence of TNFa and IFNg, that can decrease BclxL
and increase Bax), increased Fn14 expression enhanced the cell
susceptibility to death induced by TWEAK. Caspase inhibitors
prevent TWEAK-induced apoptosis, but promote reactive oxygen
species-mediated cell death. Canonical and non-canonical
NFkB activation increases the secretion of various mediators
of inflammation. IFNg, interferon-g; MAPK, mitogen-activated
protein kinase; NFkB, nuclear factor-kB; TNFa, tumor necrosis
factor-a.
Table 1 | TWEAK actions on renal cells
Cell type Action Signaling Reference
Proximal tubular cells Proliferation NFkB, MAPKs PI3K/Akt Sanz et al.45
Inflammation Canonical and non-canonical NFkB activation;
MAPKs
Gao et al.48; Sanz et al.56;
Sanz et al.57
Cell death in the presence of
TNFa/IFNg
Apoptosis: caspases and mitochondrial pathway
Necrosis: caspase-independent oxidative stress
Justo et al.33
Podocytes Inflammation NFkB and MAPKs Gao et al.48
Proliferation Unknown Gao et al.48
Mesangial cells Inflammation NFkB and MAPKs Gao et al.48; Campbell et al.52
Proliferation Unknown Gao et al.48
Apoptosis, increased in presence of IFNg Unknown Gao et al.48
Abbreviations: IFNg, interferon-g; MAPK, mitogen-activated protein kinase; NFkB, nuclear factor-kB; PI3K, phosphoinositide 3-kinase; TNFa, tumor necrosis factor-a.
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and non-canonical NFkB activation in tubular cells and
whole-kidney and tubular expression of chemokines.48,52,56,57
In addition, TWEAK leads to interstitial kidney infiltration
by macrophages and T cells.48,56,57 In addition, TWEAK
administration aggravates the glomerular and tubulointer-
stitial lesions of hyperlipidemic ApoE/ mice.37
Cell death
Loss of renal tubular cells by apoptosis characterizes both
acute kidney injury (AKI) and chronic kidney disease
(CKD).62,63 Several members of the TNFSF, such as FasL,
TNFa, and TRAIL, induce apoptosis in stressed renal
cells.64–66 TWEAK was described as a cytokine with weak
capacity to induce apoptosis, frequently requiring long
incubation periods and co-stimulation with sensitizing agents
such as interferon (IFN)g to induce apoptosis.7 However,
TWEAK alone may also promote apoptosis in neurons,
monocytes, and certain tumor cell lines.14,52,67–69 TWEAK
alone does not induce apoptosis in resting renal tubular cells.
However, TWEAK kills tubular cells in the presence of several
(not one) inflammatory mediators released during AKI, such
as the combination of TNFa and IFNg (Figure 3).33,63,70
TNFa and IFNg increased Fn14 expression in tubular cells
and this may sensitize tubular cells to TWEAK. In this regard,
non-renal cells resistant to TWEAK-induced cell death
become TWEAK sensitive when transfected with a vector
encoding hFn14.71 However, the level of Fn14 expression
cannot be the only mechanism involved in TWEAK
sensitization, as serum also increased tubular cell Fn14
expression but did not sensitize to cell death.45 By contrast,
TWEAK or IFNg alone induce mild apoptosis in mesangial
cells under basal conditions, and have a synergistic effect
when combined.48,52
The signaling pathway leading from Fn14 to cell death
remains poorly understood, as Fn14 lacks a death domain
and cannot directly recruit death domain-containing adapter
proteins. TWEAK activates the canonical NFkB pathway,
MAPK, and phosphoinositide 3-kinase/Akt signaling, but
there is no evidence of the involvement of these pathways in
TWEAK-induced apoptosis.69 However, NFkB2 activation
has been associated with TWEAK-induced cell death. Thus,
Fn14 activation recruits TNFR-associated factor-2 and
induces degradation of the cellular inhibitor of apoptosis 1
(cIAP1). TWEAK-induced cIAP1 degradation leads to
NFkB2 activation and this sensitizes immortalized tumor
cells to TNFa-induced apoptosis.72 In tubular cells, TWEAK/
TNFa/IFNg-induced apoptosis is associated with caspase-8
activation and recruitment of the mitochondrial apoptosis
pathway.33 TNFa alone may induce delayed apoptosis in
tubular cells, but the time course differs from that of
TWEAK/TNFa/IFNg.33 Caspase inhibition prevented
TWEAK/TNFa/IFNg-induced apoptosis but led to a drama-
tic increase in necrosis (Figure 3).33 This response was not
observed with TNFa alone.33 These results suggest that intra-
cellular molecular mechanisms differ between death induced
by TNFa and by a cytokine combination that includes TNFa
and TWEAK. The necrotic response observed in tubular cells
exposed to the cytokine combination and caspase inhibitors
is reminiscent of similar responses observed in other cell
types and raises doubts about the safety of pan-caspase
inhibitors in a clinical context.73 Interestingly, caspases seem
to quench intracellular oxidative stress in tubular cells
immersed in an inflammatory milieu, as antioxidants
prevented the necrotic response.33 As TWEAK also activates
NFkB2 in tubular cells, further studies should be performed
to clarify the role of this pathway in TWEAK-induced tubular
cell death.
Cell proliferation
Kidney tissue cell number is carefully regulated through the
balance between mitosis and cell death.74 Several TNFSF
cytokines, such as TNFa or FasL, can either induce apoptosis
or proliferation depending on experimental condi-
tions.67,75,76 TWEAK has a proliferative effect in numerous
cell types, including endothelial, epithelial, tumor, and
progenitor cells.8,31,34 TWEAK induces proliferation in
quiescent renal tubular cells, and this effect is enhanced in
the presence of mitogenic factors from serum (Figure 3).45
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Figure 3 | TWEAK activation of canonical and non-canonical
NFjB pathways in renal tubular cells. Fn14 engagement by
TWEAK results in early activation of the canonical NFkB pathway.
This pathway contributes to TWEAK-induced early chemokine
and inflammatory mediator production, renal macrophage
recruitment, and tubular epithelium proliferation, but it may
have additional consequences. In addition, Fn14 engagement
by TWEAK also induces delayed non-canonical NFkB activation,
contributing to the production of different chemokines, involved
in T-cell recruitment. Additional consequences of non-canonical
NFkB activation by TWEAK have not been explored. MCP-1,
monocyte chemoattractant protein 1; NFkB, nuclear factor-kB;
NIK, NF-kB-inducing kinase; p-, phosphorylated.
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Serum increases both TWEAK and Fn14 expression in
cultured tubular cells and this may facilitate an enhanced
proliferative response.45 Thus, TWEAK actions over renal
cells are modulated by the cell microenvironment. As the
Fn14 receptor is the mediator of both TWEAK-induced
proliferation and cell death.33,45 TWEAK also induces
proliferation in mesangial cells and podocytes. This suggests
that TWEAK may also have a role in glomerular pathol-
ogies characterized by cell proliferation, such as lupus
nephritis (LN).48
TWEAK-induced proliferation is cell type depen-
dent.24,31,34,50,77 However, the molecular pathways that
mediate TWEAK-induced proliferation are not well char-
acterized. TWEAK can activate cell proliferation-related
pathways, such as the NFkB, MAPKs, and phosphoinositide
3-kinase/Akt pathways.6,50,58,60,78 Some reports associate
these pathways with the proliferative effect of TWEAK in
non-renal cells.31,34,79 In tubular cells, TWEAK activates
extracellular signal-regulated kinase1/2, p38 MAPK, phos-
phoinositide 3-kinase/Akt, and NFkB, and these pathways
cooperate in TWEAK-induced proliferation in a manner that
disruption of one of them by small-molecule inhibitors
prevents tubular cell proliferation (Figure 3).45 The pro-
liferative effect of TWEAK was also observed in vivo, in
kidney tubular cells from healthy mice injected with
exogenous TWEAK.45
Both serum and inflammatory cytokines increase Fn14
expression but they sensitize to opposite TWEAK actions:
cell proliferation and apoptosis, respectively. As the Fn14
receptor mediates both the proliferative and the lethal
potential of TWEAK, we have to hypothesize that serum
and inflammatory cytokines present in the cell microenvir-
onment may have opposite effects on other apoptosis or cell
cycle-regulatory proteins.45 Factors present in the serum may
upregulate the pathways involved in TWEAK-induced
proliferation, such as MAPK, or inhibit the pathways
involved in TWEAK-induced cell death. Serum and inflam-
matory cytokines have different effects on cell survival
proteins. Thus, in cultured tubular cells, TNFa increases
Bax and SMAC/Diablo expression and downregulates BclxL,
whereas the serum has opposite effects.63,80 In this regard,
15d-PGJ2 sensitizes colon cancer cells to TWEAK-induced
cell death by reducing BclxL expression and inducing BAX
expression.81
Fn14/TWEAK EXPRESSION IN TISSUE INJURY
Fn14 expression is relatively low in most resting tissues, but it
is considerably upregulated in injured tissues. Experimental
models in which high Fn14 expression has been observed
include chronic liver injury,34 denervation-induced skeletal
muscle atrophy,29 myocardial infarction,43 colitis,36 auto-
immune encephalomyelitis,35 the vasculature after balloon
catheter injury,15 and others. Fn14 is also upregulated in
human adipose tissues in severe obesity,42 periodontitis,82
ischemic stroke,83 atherosclerosis,84 and cancer.8 In contrast,
TWEAK is expressed at high levels in numerous tissues.1,9
TWEAK can also be upregulated in tissues damaged by acute
injury, inflammatory disease, or cancer.40 However, changes
in TWEAK gene expression and protein are usually not as
dramatic as those observed for Fn14.
Fn14/TWEAK EXPRESSION IN EXPERIMENTAL AND HUMAN
RENAL INJURY
Fn14 and TWEAK expression is also modulated in kidney
injury. Although experimental animal models have been
characterized in more detail, some human data are also
available. Fn14 was upregulated in the kidneys in experi-
mental and clinical AKI.33,44 By contrast, kidney TWEAKwas
upregulated in experimental AKI, but downregulated in
experimental LN.33,85 TWEAK was upregulated in peripheral
blood leukocytes and in urine samples obtained from lupus
patients.86,87
Fn14 expression in renal disease
In healthy kidneys, Fn14 expression is low, but Fn14 is
upregulated after kidney injury. Fn14 is dramatically
increased in two different experimental models of AKI,
induced by a folic acid overdose or by ischemia–reperfu-
sion.33,44 Both models share an initial phase of tubular cell
death and interstitial inflammation, followed by compensa-
tory tubular cell proliferation. Both share an early (within
6 h) increase in whole-kidney Fn14 mRNA and protein levels.
However, the temporal pattern differed, as Fn14 upregulation
was sustained until 72 h after folic acid, but not after kidney
ischemia–reperfusion.33,44,56 Both proximal and distal tubules
express Fn14, which is mainly localized to injured and dilated
tubules.33 Fn14 expression is also increased in the remnant
kidney in a uninephrectomy model.45 This model differs
from AKI in the absence of cell death and renal inflamma-
tion, and is characterized by compensatory kidney growth
through hyperplasia and hypertrophy of tubular cells.45
Fn14 upregulation was also observed in human ischemic
kidneys.44 However, its expression in other human causes of
AKI or following uninephrectomy has not been studied.
TWEAK expression in renal disease
Renal TWEAK expression in physiological conditions is low
but increases in experimental AKI. TWEAK changes are
milder and delayed as compared with Fn14, peaking at
24 h.33,44 TWEAK colocalizes with Fn14 in proximal tubules,
suggesting that tubular cells may be exposed to both
sTWEAK and mTWEAK from neighboring cells that may
have juxtacrine actions.6,12,33 Colocalization of TWEAK and
Fn14 in injured tubules was not observed in experimental
ischemia–reperfusion-induced AKI.44
TWEAK, mRNA, and protein, in peripheral blood
mononuclear cells from systemic lupus erythematosus
(SLE) patients were significantly higher than in rheumatoid
arthritis patients or healthy controls.87 They were higher in
SLE patients with LN. Elevated production of TWEAK
correlated positively with the SLE diseases activity index,
proteinuria, serum anti-dsDNA, IL-10, and monocyte
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chemoattractant protein 1, but inversely with serum C3.87
Increased expression of TWEAK and TNFSF members,
TRAIL and FasL, on lupus T cells was responsible for the
autologous monocyte death induced by lupus T cells.14
In early reports, reduced TWEAK mRNA levels that
preceded LN were found in kidneys from male lupus-prone
BXSB and NZ mice bearing the Yaa mutation, when
compared with females.85 However, functional studies have
firmly established the role of TWEAK/Fn14 in LN.47,88
Aldosterone blockade ameliorated experimental LN in female
NZB/W F1 mice and reduced kidney TWEAK, TRAIL, and
FasL mRNA expression.89 Table 2 summarizes available
information on TWEAK/Fn14 and LN.
CD163 is a TWEAK-binding, hemoglobin scavenger
receptor mainly expressed by macrophages. Increased kidney
CD163 expression has been observed in human glomerular
hematuria-associated AKI.90 TWEAK might compete with
hemoglobin for CD163 binding.
FUNCTIONAL STUDIES OF TWEAK/Fn14 IN EXPERIMENTAL
RENAL INJURY
The functional relevance of TWEAK/Fn14 for kidney injury
has been addressed in animal models (Table 3).
Acute kidney injury
An overdose of folic acid induces AKI in humans91 and
mice.63,92 Experimental folic acid-induced AKI shares with
human AKI the presence of tubular cell apoptosis, compen-
satory tubular cell proliferation leading to regeneration,
inflammatory cell infiltration, and, in a chronic phase, mild
fibrosis.63,92 Kidney tubular cell TWEAK and Fn14 were
upregulated in experimental folic acid-induced AKI. More-
over, during AKI, multiple cytokines are released, including
TNFa and IFNg.33,56,63 The precise role of TWEAK/Fn14 in
AKI was difficult to predict, as cell culture and in vivo results
of systemic TWEAK administration suggested potential
beneficial or deleterious actions of TWEAK in AKI. Thus,
TWEAK may induce cell death in an inflammatory environ-
ment, but may also have a proliferative effect on tubular cells
Table 2 | Evidence linking TWEAK/Fn14 to lupus nephritis (LN)
Experimental models
Descriptive evidence
Decreased renal TWEAK mRNA preceding LN in male lupus-prone
BXSB and NZ mice bearing the Yaa mutation.85
Kidney TWEAK is decreased by aldosterone targeting in female
NZB/W F1 mice.89
Functional evidence
LN improved by anti-TWEAK-neutralizing antibody in Fn14 KO
mice.88
Clinical evidence
Descriptive evidence
Increased TWEAK mRNA and protein in peripheral blood
mononuclear cells from SLE patients.87
Increased TWEAK synthesis by T cells from SLE patients.14
Increased uTWEAK in active LN, which correlates with renal disease
activity.86,116
Functional evidence: none
Abbreviations: SLE, systemic lupus erythematosus; uTWEAK, urinary TWEAK.
Table 3 | In vivo TWEAK/Fn14 modulation in experimental renal disease
Experimental model Approach Results Reference
AKI folic acid overdose Anti-TWEAK-neutralizing Ab mRenal function Sanz et al.56;
kInflammation Sanz et al.45; Sanz et al.57
TWEAK KO mice mRenal function Sanz et al.45
kInflammation Sanz et al.57
kCell death
kProliferation
AKI ischemia–reperfusion Anti-Fn14-neutralizing Ab mRenal function Hotta et al.44
kInflammation
kCell death
kFibrosis
Uninephrectomy-induced renal hyperplasia TWEAK KO mice kProliferation Sanz et al.45
TWEAK administration mProliferation
ApoE/ mice nephropathy Anti-TWEAK-neutralizing Ab kInflammation Munoz-Garcia et al.37
TWEAK administration mInflammation
SLE (cGVH model) Anti-TWEAK-neutralizing Ab =Autoantibody titer Zhao et al.88
kProteinuria
kInflammation
kIgG deposition
Fn14 KO mice =Autoantibody titer Zhao et al.88
kProteinuria
kInflammation
kIgG deposition
Fn14+/+ kidney-resident cells No changes in initial nephritis Molano et al.47
Fn14/ hematopoietic cells
Fn14/ kidney resident cells Delayed nephritis Molano et al.47
Fn14+/+ hematopoietic cells
Abbreviations: Ab, antibody; AKI, acute kidney injury; cGVH, chronic graft-versus-host; KO, knockout; SLE, systemic lupus erythematosus.
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or progenitor cells or contribute to recruit macrophages that
might participate in tissue injury or repair. Targeting
TWEAK in vivo allowed studying the end result of these
interactions in the AKI microenvironment. Two different
approaches, neutralizing anti-TWEAK antibodies or TWEAK
knockout mice successfully decreased peak serum creatinine
and led to a significantly milder histological injury in
folic acid-induced AKI.45,56 Moreover, TWEAK targeting
did not impair functional recovery.45 An additional approach,
Fn14 blockade also significantly decreased tubular injury
in a different AKI model, induced by renal ischemia–
reperfusion.44
In AKI, an initial wave of cell death is followed by tubular
cell proliferation that repopulates the tubules and promotes
recovery. As TWEAK induces proliferation in tubular cells,
we could hypothesize that TWEAK may contribute to kidney
recovery. In this sense, TWEAK knockout mice showed a
decreased peak of tubular apoptosis followed by a decreased
peak of proliferation,45 and Fn14 blockade reduces apoptosis
of renal cells induced by ischemia–reperfusion.44 Then, based
on: (1) the ability of TWEAK to induce tubular cell death
in culture in an inflammatory environment, (2) the presence
of inflammation during AKI, (3) the temporal relationship
between cell death and proliferation in AKI, and (4) the
beneficial effect of TWEAK or Fn14 targeting on AKI
outcome, we can speculate that TWEAK targeting decreased
the early cell death peak, thus leading to a lesser need of
repair proliferation during recovery. However, these results
do not discard a proliferative repair role of TWEAK during
the recovery phase in AKI that cannot be evidenced by
the experimental designs published because of the more
important role of TWEAK in generating the initial tissue
injury.
During AKI, inflammatory cell infiltration depends on
the local expression of inflammatory cytokines.53,93 TWEAK
targeting in folic acid-induced AKI decreased the tubular
expression of chemokines (monocyte chemoattractant protein
1, RANTES, and CCL21) and interstitial inflammation by
macrophages and T lymphocytes.56,57 However, high-kidney
IL-6 mRNA in the course of AKI is TWEAK independent.56
Thus, although TWEAK modulates IL-6 expression in
cultured tubular cells, in the AKI model, there are other,
more potent, stimuli that regulate the IL-6 expression. Similar
beneficial effects were observed by blocking Fn14 in experi-
mental renal ischemia–reperfusion-induced AKI.44 TWEAK-
induced inflammation is usually considered to be mediated by
canonical NFkB activation.8,56 In this regard, numerous
studies have confirmed canonical NFkB activation during
AKI.55 However, non-canonical NFkB pathways involving
NFkB2 and RelB are also activated in a TWEAK-dependent
manner during AKI.57 Thus, TWEAK targeting during AKI
prevented tubular cell non-canonical NFkB activation and
decreased the kidney expression of the NFkB2/RelB target
gene, CCL21, and T-cell recruitment.57
In summary, preemptive TWEAK or Fn14 targeting
during AKI improved renal function and decreased tubular
cell death and compensatory tubular cell proliferation, as well
as interstitial inflammation. There is currently no informa-
tion on the therapeutic effect of TWEAK targeting once renal
injury has been established.
Hyperlipidemic nephropathy of ApoE/ mice
ApoE/ mice display spontaneous hypercholesterolemia
and atherosclerosis that are aggravated by a lipid-rich
diet.94 In addition, ApoE/ mice develop spontaneous
glomerular injury with age that is accelerated by a high-fat,
high-cholesterol diet.95–97 This is characterized by mesangial
expansion, glomerular inflammation, and increased glome-
rulosclerosis index.95–97 A 9-day course of neutralizing
anti-TWEAK antibodies ameliorated histological glomerular
and tubulointerstitial features of the nephropathy of ApoE/
mice fed a lipid-rich diet.37 In addition, TWEAK targeting
decreased kidney NFkB activation, chemokine mRNA expres-
sion, and macrophage infiltration. By contrast, TWEAK
administration aggravated glomerular and tubulointerstitial
lesions.
Kidney growth after unilateral nephrectomy
An acute loss of renal mass, such as that induced by unilateral
nephrectomy, is followed by compensatory renal hypertrophy
and hyperplasia.98 Clinical examples include nephrectomy for
benign or malignant conditions, living kidney donation, and
kidney transplant recipients. Growth factors and cytokines,
such as growth hormone and insulin-like growth factor, have
been implicated in compensatory renal growth after uni-
nephrectomy.99 In addition, TNFSF cytokines, such as TNFa
participate both in parenchymal cell injury and in prolifera-
tion after loss of the tissue mass. Thus, TNFa promotes
hepatocyte apoptosis, but type 1 TNF receptor is required for
compensatory proliferation after partial hepatectomy.75,76
TWEAK induces cell proliferation in various cell types and
might contribute to pathological or compensatory hyper-
plasia after acute injury. Fn14 expression is upregulated
during liver regeneration and in hepatocellular carcinoma,16
and TWEAK induces proliferation in liver oval cells and
liver progenitor cells in vivo.23,34 Moreover, Fn14 contributes
to nerve regeneration.100 TWEAK induces proliferation
in astrocytes, synoviocytes,50,101 and in cardiomyocytes,31
and the TWEAK/Fn14 pathway regulates skeletal muscle
precursor cells.41
In normal murine kidneys, systemic TWEAK administra-
tion promotes tubular cell proliferation.45 Renal growth
following uninephrectomy is characterized by tubular cell
proliferation and hypertrophy in the absence of renal injury.
In the remaining kidney, after unilateral nephrectomy,
tubular Fn14 expression is increased within days, but there
are no changes in TWEAK or in the inflammatory cyto-
kines associated with TWEAK-induced cell death, such as
TNFa and IFNg.45 Endogenous or exogenous, systemically
administered, TWEAK increased tubular cell proliferation
observed within days in the remaining kidney following
unilateral nephrectomy.45 By contrast, absence of TWEAK in
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knockout mice decreased tubular cell proliferation in the
remaining kidney. These results suggest that Fn14 facilitates
tubular cell proliferation in compensatory renal growth
following unilateral nephrectomy by sensitizing cells to
TWEAK and cooperating with other mitogens as observed
in culture. This information may be used to promote kidney
growth in clinical situations characterized by an acute non-
inflammatory loss of kidney mass and its relevance in tissue
engineering should be explored.
Lupus nephritis
TWEAK has a proinflammatory effect in glomerular
mesangial cells and podocytes,48,52 suggesting a possible role
of the TWEAK/Fn14 pathway in the pathogenesis of glome-
rular injury. This role has been explored in experimental LN
as a model of immune-mediated glomerular disease. In the
chronic graft-versus-host murine model of LN, the absence
of Fn14 or TWEAK blockade decreased the severity of
glomerulonephritis, as assessed by proteinuria, glomerular
IgG deposition, kidney cytokine expression, and macrophage
infiltration.88 The improvement in glomerular injury was
observed in the absence of changes in autoantibody
production.88 The relative contribution of Fn14 expression
by resident kidney cells or by myeloid cells (macrophages)
that infiltrate the kidney in LN was addressed in two groups
of chimeric mice. One chimera expressed Fn14 in kidney-
resident cells, whereas bone marrow-derived cells lacked
Fn14. In the other chimera, Fn14 expression was restricted
to bone marrow-derived cells.47 Fn14 expression only by
kidney-resident cells was sufficient to promote an early
inflammatory response and a rapid increase in albuminuria
as a marker of glomerular injury. However, Fn14 signaling
from bone marrow-derived cells has a role in albuminuria
and inflammation at a later stage of the disease. The
recruitment of inflammatory cells to the kidney driven by
resident cell Fn14 expression is consistent with cell culture
studies and in vivo studies showing that TWEAK induces
chemokine secretion in kidney cells leading to macrophage
chemotaxis.48,52,56 This observation is also consistent with
the current model of kidney inflammation in which resident
kidney cells contribute to initiation of nephritis, in this case
through the TWEAK/Fn14 pathway, whereas infiltrating
macrophages have a later role, when they have migrated to
the kidney.
BIOMARKER POTENTIAL OF TWEAK
The first evidence suggesting that sTWEAK may be a
biomarker was the observation that sTWEAK levels in the
plasma were decreased in patients with carotid atherosclerosis
compared with healthy subjects.84 Decreased sTWEAK levels
are also found in other cardiovascular diseases, such as
peripheral artery disease,102 coronary artery disease,103 heart
failure,104,105 and abdominal aortic aneurysms.106 The
decreased sTWEAK levels could be a consequence of upregu-
lated Fn14 expression in injured vessels.49 In addition,
sTWEAK may be cleared through the TWEAK–CD163
interaction with CD163-expressing macrophages.102 CD163
is increased in the plasma of peripheral artery disease patients
and the TWEAK–CD163 interaction was observed in vivo,
probably contributing to decreased sTWEAK plasma con-
centration.22,102 Serum sTWEAK concentration decreases
progressively with increasing CKD stage and are lowest in
patients with end-stage renal disease on chronic hemo-
dialysis.107,108 They are also low in type 2 diabetes mellitus.
Kidney disease and diabetes have an additive effect on
decreasing sTWEAK levels.109 Circulating sTWEAK levels are
a potential biomarker of cardiovascular risk in CKD. Thus,
hemodialysis patients having sTWEAK concentrations in the
higher range for end-stage renal disease patients were at
higher risk of death. This was especially true for the subgroup
of patients with high levels of inflammatory biomarkers.107
These seem to be counterintuitive findings: sTWEAK levels
are low in dialysis, but within these low levels, patients with
higher levels are at increased risk. However, these findings
may be partially explained by the increased expression of
Fn14 in injured vessels, which enhances their sensitivity to
TWEAK. Indeed, inflammatory cytokines are some of the
most potent drivers of Fn14 expression.84 We hypothesize
that a reset of the system may take place in CKD and vascular
injury in which sTWEAK may be decreased by clearance
through competing high levels of CD163 and Fn14 receptors.
Under these circumstances, any further increase in sTWEAK
over the low basal levels might be deleterious through
activation of the increased amounts of Fn14 in vascular
cells. Furthermore, low sTWEAK plasma levels in CKD may
be a biomarker of endothelial dysfunction.108,110 Indeed,
sTWEAK levels are modulated by antihypertensive drugs that
improve endothelial function, suggesting that sTWEAK could
be a surrogate therapeutic target.110 In hypertensive diabetic
CKD stage I patients, treatment for 12-weeks with valsartan
alone or in combination with amlodipine resulted in
increased sTWEAK plasma levels.110 More importantly, the
changes observed in sTWEAK levels were independently
associated with improvement in flow-mediated dilation.110
However, beyond these changes of sTWEAK in response to
antihypertensive medication, little is known about the role of
TWEAK in hypertension or its complications. In addition,
statins may also modulate the system. Atorvastatin prevented
the upregulation of Fn14 expression induced by inflamma-
tory cytokines in vascular smooth muscle cells.49
By contrast, sTWEAK levels are increased in patients
with acute myocardial infarction, hemophagocytic lympho-
histiocytosis, multiple myeloma, and SLE.111–114 LN is
characterized by flares.115 Urinary TWEAK (uTWEAK) and
serum sTWEAK are potential biomarkers in LN.86,113 In SLE
patients, uTWEAK correlated positively with LN activity. It
was postulated that uTWEAK levels did not reflect damage to
the glomerular filtration barrier, but indicated local inflam-
matory activity. The potential of uTWEAK as a candidate
clinical biomarker for LN was recently corroborated in
a multicenter cohort study, while plasma sTWEAK levels
were not better that uTWEAK.86 In this regard, uTWEAK in
Kidney International (2011) 80, 708–718 715
AB Sanz et al.: TWEAK, a multifunctional cytokine in kidney injury rev iew
patients with LN correlate with renal disease inflammatory
activity and are increased when compared with SLE patients
with similar Systemic Lupus Erythematosus Disease Activity
Index severity scores but without LN, other rheumatic disease
patients, CKD patients, and healthy controls.116 In a prospective
study of 13 patients, uTWEAK started to increase 4–6 months
before a LN flare, peaked with the flare, and later decreased in
response to therapy.116 These results are consistent with reports
that describe an inflammatory role of TWEAK in LN.47,88
LN is usually associated with proteinuria. However,
uTWEAK levels were not correlated with proteinuria in LN
patients.86 In this regard, the most frequent LN classes (III and
IV) are inflammatory glomerular diseases that may not be
representative of proteinuric kidney disease mainly characte-
rized by podocyte injury in the absence of overt inflammation.
FUTURE PERSPECTIVES
Current preclinical data indicate that the TWEAK/Fn14
system may be a therapeutic target in kidney injury. However,
data on its functional relevance for kidney injury have been
obtained only in experimental animal models and there is an
insufficient understanding of the role of TWEAK in human
renal disease. Furthermore, there are little data on the
relationship of TWEAK/Fn14 with hypertension, podocyte
injury, and proteinuric kidney diseases other than LN. In the
near future, we will have the first data on TWEAK/Fn14
targeting in human subjects, as clinical trials are under-
way for BIIB023-neutralizing anti-TWEAK antibodies in
rheumatoid arthritis and PDL192 anti-TWEAK receptor
antibodies in subjects with advanced solid tumors (http://
clinicaltrials.gov/ct2/show/NCT00771329). Demonstration of
the safety of these approaches in humans will accelerate
translational research in kidney disease. However, there is a
need for further drug development in this area, including
Fn14-specific antagonists. Measuring sTWEAK levels in
serum/plasma or urine may provide diagnostic information
on CKD patient outcomes and the activity of LN. Further
studies are required to confirm these findings by independent
groups and to establish the added value of integrating
sTWEAK levels in diagnostic algorithms.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
FIS PS09/00447, Sociedad Espan˜ola de Nefrologia, Fundacion Renal
In˜igo Alvarez de Toledo, ISCIII-RETIC REDinREN/RD06/0016, Programa
Intensificacio´n Actividad Investigadora (ISCIII/Agencia Laı´n-Entralgo/
CM) to AO, FIS to ABS, MDS-N.
REFERENCES
1. Chicheportiche Y, Bourdon PR, Xu H et al. TWEAK, a new secreted ligand
in the tumor necrosis factor family that weakly induces apoptosis.
J Biol Chem 1997; 272: 32401–32410.
2. Foster D, Parrish-Novak J, Fox B et al. Cytokine-receptor pairing:
accelerating discovery of cytokine function. Nat Rev Drug Discov 2004; 3:
160–170.
3. Grewal IS. Overview of TNF superfamily: a chest full of potential
therapeutic targets. Adv Exp Med Biol 2009; 647: 1–7.
4. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor
superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501.
5. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the
TNF superfamily. Trends Biochem Sci 2002; 27: 19–26.
6. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored
TWEAK can function as a juxtacrine signaling molecule and activate
the NF-kappaB pathway. J Biol Chem 2010; 285: 17432–17441.
7. Nakayama M, Kayagaki N, Yamaguchi N et al. Involvement of TWEAK in
interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000;
192: 1373–1380.
8. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology
and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411–425.
9. Marsters SA, Sheridan JP, Pitti RM et al. Identification of a ligand for
the death-domain-containing receptor Apo3. Curr Biol 1998; 8:
525–528.
10. De Kooten A, Vermeulen L, Vialard J et al. Involvement of GSK-3beta in
TWEAK-mediated NF-kappaB activation. FEBS Lett 2004; 566: 60–64.
11. Baxter FO, Came PJ, Abell K et al. IKKbeta/2 induces TWEAK and
apoptosis in mammary epithelial cells. Development 2006; 133:
3485–3494.
12. Roos C, Wicovsky A, Muller N et al. Soluble and transmembrane TNF-like
weak inducer of apoptosis differentially activate the classical and
noncanonical NF-kappa B pathway. J Immunol 2010; 185: 1593–1605.
13. Kaptein A, Jansen M, Dilaver G et al. Studies on the interaction between
TWEAK and the death receptor WSL-1/TRAMP (DR3). FEBS Lett 2000;
485: 135–141.
14. Kaplan MJ, Lewis EE, Shelden EA et al. The apoptotic ligands TRAIL,
TWEAK, and Fas ligand mediate monocyte death induced by autologous
lupus T cells. J Immunol 2002; 169: 6020–6029.
15. Wiley SR, Cassiano L, Lofton T et al. A novel TNF receptor family member
binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15:
837–846.
16. Feng SL, Guo Y, Factor VM et al. The Fn14 immediate-early response
gene is induced during liver regeneration and highly expressed in both
human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:
1253–1261.
17. Meighan-Mantha RL, Hsu DK, Guo Y et al. The mitogen-inducible Fn14
gene encodes a type I transmembrane protein that modulates fibroblast
adhesion and migration. J Biol Chem 1999; 274: 33166–33176.
18. Brown SA, Richards CM, Hanscom HN et al. The Fn14 cytoplasmic tail
binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5
and mediates nuclear factor-kappaB activation. Biochem J 2003; 371:
395–403.
19. He F, Dang W, Saito K et al. Solution structure of the cysteine-rich
domain in Fn14, a member of the tumor necrosis factor receptor
superfamily. Protein Sci 2009; 18: 650–656.
20. Polek TC, Talpaz M, Darnay BG et al. TWEAK mediates signal
transduction and differentiation of RAW264.7 cells in the absence of
Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003;
278: 32317–32323.
21. Bover LC, Cardo-Vila M, Kuniyasu A et al. A previously unrecognized
protein-protein interaction between TWEAK and CD163: potential
biological implications. J Immunol 2007; 178: 8183–8194.
22. Moreno JA, Munoz-Garcia B, Martin-Ventura JL et al. The CD163-
expressing macrophages recognize and internalize TWEAK: potential
consequences in atherosclerosis. Atherosclerosis 2009; 207: 103–110.
23. Jakubowski A, Ambrose C, Parr M et al. TWEAK induces liver progenitor
cell proliferation. J Clin Invest 2005; 115: 2330–2340.
24. Lynch CN, Wang YC, Lund JK et al. TWEAK induces angiogenesis and
proliferation of endothelial cells. J Biol Chem 1999; 274: 8455–8459.
25. Maecker H, Varfolomeev E, Kischkel F et al. TWEAK attenuates the
transition from innate to adaptive immunity. Cell 2005; 123: 931–944.
26. Nakayama M, Harada N, Okumura K et al. Characterization of murine
TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem
Biophys Res Commun 2003; 306: 819–825.
27. Naumann M, Nieters A, Hatada EN et al. NF-kappa B precursor
p100 inhibits nuclear translocation and DNA binding of NF-kappa
B/rel-factors. Oncogene 1993; 8: 2275–2281.
28. Tran NL, McDonough WS, Savitch BA et al. The tumor necrosis factor-like
weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible
14 (Fn14) signaling system regulates glioma cell survival via NFkappaB
pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;
280: 3483–3492.
29. Mittal A, Bhatnagar S, Kumar A et al. The TWEAK-Fn14 system is a critical
regulator of denervation-induced skeletal muscle atrophy in mice.
J Cell Biol 2010; 188: 833–849.
716 Kidney International (2011) 80, 708–718
rev iew AB Sanz et al.: TWEAK, a multifunctional cytokine in kidney injury
30. Wang D, Fung JN, Tuo Y et al. TWEAK/Fn14 promotes apoptosis of
human endometrial cancer cells via caspase pathway. Cancer Lett 2010;
294: 91–100.
31. Novoyatleva T, Diehl F, van Amerongen MJ et al. TWEAK is a positive
regulator of cardiomyocyte proliferation. Cardiovasc Res 2010; 85:
681–690.
32. Tiller G, Fischer-Posovszky P, Laumen H et al. Effects of TWEAK (TNF
superfamily member 12) on differentiation, metabolism, and secretory
function of human primary preadipocytes and adipocytes.
Endocrinology 2009; 150: 5373–5383.
33. Justo P, Sanz AB, Sanchez-Nino MD et al. Cytokine cooperation in renal
tubular cell injury: the role of TWEAK. Kidney Int 2006; 70: 1750–1758.
34. Tirnitz-Parker JE, Viebahn CS, Jakubowski A et al. Tumor necrosis factor-
like weak inducer of apoptosis is a mitogen for liver progenitor cells.
Hepatology 2010; 52: 291–302.
35. Desplat-Jego S, Creidy R, Varriale S et al. Anti-TWEAK monoclonal
antibodies reduce immune cell infiltration in the central nervous system
and severity of experimental autoimmune encephalomyelitis. Clin
Immunol 2005; 117: 15–23.
36. Dohi T, Borodovsky A, Wu P et al. TWEAK/Fn14 pathway: a
nonredundant role in intestinal damage in mice through a TWEAK/
intestinal epithelial cell axis. Gastroenterology 2009; 136: 912–923.
37. Munoz-Garcia B, Moreno JA, Lopez-Franco O et al. Tumor necrosis
factor-like weak inducer of apoptosis (TWEAK) enhances vascular and
renal damage induced by hyperlipidemic diet in ApoE-knockout mice.
Arterioscler Thromb Vasc Biol 2009; 29: 2061–2068.
38. Munoz-Garcia B, Madrigal-Matute J, Moreno JA et al. TWEAK-Fn14
interaction enhances plasminogen activator inhibitor 1 and tissue factor
expression in atherosclerotic plaques and in cultured vascular smooth
muscle cells. Cardiovasc Res 2011; 89: 225–233.
39. Haile WB, Echeverry R, Wu J et al. The interaction between tumor
necrosis factor-like weak inducer of apoptosis and its receptor fibroblast
growth factor-inducible 14 promotes the recruitment of neutrophils
into the ischemic brain. J Cereb Blood Flow Metab 2010; 30: 1147–1156.
40. Burkly LC, Michaelson JS, Hahm K et al. TWEAKing tissue remodeling by
a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and
disease. Cytokine 2007; 40: 1–16.
41. Girgenrath M, Weng S, Kostek CA et al. TWEAK, via its receptor Fn14, is a
novel regulator of mesenchymal progenitor cells and skeletal muscle
regeneration. EMBO J 2006; 25: 5826–5839.
42. Vendrell J, Maymo-Masip E, Tinahones F et al. Tumor necrosis-like weak
inducer of apoptosis as a proinflammatory cytokine in human adipocyte
cells: up-regulation in severe obesity is mediated by inflammation but
not hypoxia. J Clin Endocrinol Metab 2010; 95: 2983–2992.
43. Mustonen E, Sakkinen H, Tokola H et al. Tumour necrosis factor-like
weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac
remodelling in rats. Acta Physiol (Oxf) 2010; 199: 11–22.
44. Hotta K, Sho M, Yamato I et al. Direct targeting of fibroblast growth
factor-inducible 14 protein protects against renal ischemia reperfusion
injury. Kidney Int 2011; 79: 179–188.
45. Sanz AB, Sanchez-Nino MD, Izquierdo MC et al. Tweak induces
proliferation in renal tubular epithelium: a role in uninephrectomy
induced renal hyperplasia. J Cell Mol Med 2009; 13: 3329–3342.
46. Kim SH, Kang YJ, Kim WJ et al. TWEAK can induce pro-inflammatory
cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004;
68: 396–399.
47. Molano A, Lakhani P, Aran A et al. TWEAK stimulation of kidney resident
cells in the pathogenesis of graft versus host induced lupus nephritis.
Immunol Lett 2009; 125: 119–128.
48. Gao HX, Campbell SR, Burkly LC et al. TNF-like weak inducer of apoptosis
(TWEAK) induces inflammatory and proliferative effects in human kidney
cells. Cytokine 2009; 46: 24–35.
49. Munoz-Garcia B, Martin-Ventura JL, Martinez E et al. Fn14 is upregulated
in cytokine-stimulated vascular smooth muscle cells and is expressed in
human carotid atherosclerotic plaques: modulation by atorvastatin.
Stroke 2006; 37: 2044–2053.
50. Donohue PJ, Richards CM, Brown SA et al. TWEAK is an endothelial cell
growth and chemotactic factor that also potentiates FGF-2 and VEGF-A
mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23: 594–600.
51. Chorianopoulos E, Heger T, Lutz M et al. FGF-inducible 14-kDa
protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in
cardiomyocytes and mediates nuclear factor-kappaB activation by
TWEAK. Basic Res Cardiol 2010; 105: 301–313.
52. Campbell S, Burkly LC, Gao HX et al. Proinflammatory effects of TWEAK/
Fn14 interactions in glomerular mesangial cells. J Immunol 2006; 176:
1889–1898.
53. van KC, Daha MR, van Es LA. Tubular epithelial cells: a critical cell type in
the regulation of renal inflammatory processes. Exp Nephrol 1999; 7:
429–437.
54. de Haij S, Daha MR, van KC. Mechanism of steroid action in renal
epithelial cells. Kidney Int 2004; 65: 1577–1588.
55. Sanz AB, Sanchez-Nino MD, Ramos AM et al. NF-kappaB in renal
inflammation. J Am Soc Nephrol 2010; 21: 1254–1262.
56. Sanz AB, Justo P, Sanchez-Nino MD et al. The cytokine TWEAK
modulates renal tubulointerstitial inflammation. J Am Soc Nephrol
2008; 19: 695–703.
57. Sanz AB, Sanchez-Nino MD, Izquierdo MC et al. TWEAK activates the
non-canonical NFkappaB pathway in murine renal tubular cells:
modulation of CCL21. PLoS One 2010; 5: e8955.
58. Saitoh T, Nakayama M, Nakano H et al. TWEAK induces NF-kappaB2
p100 processing and long lasting NF-kappaB activation. J Biol Chem
2003; 278: 36005–36012.
59. Banas B, Wornle M, Berger T et al. Roles of SLC/CCL21 and CCR7 in
human kidney for mesangial proliferation, migration, apoptosis, and
tissue homeostasis. J Immunol 2002; 168: 4301–4307.
60. Ando T, Ichikawa J, Wako M et al. TWEAK/Fn14 interaction regulates
RANTES production, BMP-2-induced differentiation, and RANKL
expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther
2006; 8: R146.
61. Li H, Mittal A, Paul PK et al. Tumor necrosis factor-related weak
inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9)
production in skeletal muscle through the activation of nuclear
factor-kappaB-inducing kinase and p38 mitogen-activated protein
kinase: a potential role of MMP-9 in myopathy. J Biol Chem 2009; 284:
4439–4450.
62. Solez K, Morel-Maroger L, Sraer JD. The morphology of ‘acute tubular
necrosis’ in man: analysis of 57 renal biopsies and a comparison with the
glycerol model. Medicine (Baltimore) 1979; 58: 362–376.
63. Ortiz A, Lorz C, Catalan MP et al. Expression of apoptosis regulatory
proteins in tubular epithelium stressed in culture or following acute
renal failure. Kidney Int 2000; 57: 969–981.
64. Lorz C, Benito-Martin A, Boucherot A et al. The death ligand TRAIL in
diabetic nephropathy. J Am Soc Nephrol 2008; 19: 904–914.
65. Ortiz A, Bustos C, Alonso J et al. Involvement of tumor necrosis
factor-alpha in the pathogenesis of experimental and human
glomerulonephritis. Adv Nephrol Necker Hosp 1995; 24: 53–77.
66. Ortiz A, Lorz C, Egido J. New kids in the block: the role of FasL and
Fas in kidney damage. J Nephrol 1999; 12: 150–158.
67. Alderson MR, Armitage RJ, Maraskovsky E et al. Fas transduces activation
signals in normal human T lymphocytes. J Exp Med 1993; 178:
2231–2235.
68. Potrovita I, Zhang W, Burkly L et al. Tumor necrosis factor-like weak
inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24:
8237–8244.
69. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in
cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.
Results Probl Cell Differ 2009; 49: 145–160.
70. Goes N, Urmson J, Vincent D et al. Acute renal injury in the interferon-
gamma gene knockout mouse: effect on cytokine gene expression.
Transplantation 1995; 60: 1560–1564.
71. Nakayama M, Ishidoh K, Kojima Y et al. Fibroblast growth factor-
inducible 14 mediates multiple pathways of TWEAK-induced cell death.
J Immunol 2003; 170: 341–348.
72. Vince JE, Chau D, Callus B et al. TWEAK-FN14 signaling induces
lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor
cells to TNFalpha. J Cell Biol 2008; 182: 171–184.
73. Cauwels A, Janssen B, Waeytens A et al. Caspase inhibition causes
hyperacute tumor necrosis factor-induced shock via oxidative stress and
phospholipase A2. Nat Immunol 2003; 4: 387–393.
74. Ortiz A, Justo P, Catalan MP et al. Apoptotic cell death in renal injury: the
rationale for intervention. Curr Drug Targets Immune Endocr Metabol
Disord 2002; 2: 181–192.
75. Webber EM, Bruix J, Pierce RH et al. Tumor necrosis factor primes
hepatocytes for DNA replication in the rat. Hepatology 1998; 28:
1226–1234.
76. Yamada Y, Webber EM, Kirillova I et al. Analysis of liver regeneration in
mice lacking type 1 or type 2 tumor necrosis factor receptor:
requirement for type 1 but not type 2 receptor. Hepatology 1998; 28:
959–970.
77. Desplat-Jego S, Varriale S, Creidy R et al. TWEAK is expressed by
glial cells, induces astrocyte proliferation and increases EAE severity.
J Neuroimmunol 2002; 133: 116–123.
Kidney International (2011) 80, 708–718 717
AB Sanz et al.: TWEAK, a multifunctional cytokine in kidney injury rev iew
78. Vincent C, Findlay DM, Welldon KJ et al. Pro-inflammatory cytokines
TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce
the mitogen-activated protein kinase (MAPK)-dependent expression of
sclerostin in human osteoblasts. J Bone Miner Res 2009; 24: 1434–1449.
79. Scholzke MN, Rottinger A, Murikinati S et al. TWEAK regulates
proliferation and differentiation of adult neural progenitor cells. Mol Cell
Neurosci 2011; 46: 325–332.
80. Justo P, Sanz A, Lorz C et al. Expression of Smac/Diablo in tubular
epithelial cells and during acute renal failure. Kidney Int Suppl 2003; 86:
S52–S56.
81. Dionne S, Levy E, Levesque D et al. PPARgamma ligand 15-deoxy-delta
12,14-prostaglandin J2 sensitizes human colon carcinoma cells to
TWEAK-induced apoptosis. Anticancer Res 2010; 30: 157–166.
82. Kataria NG, Bartold PM, Dharmapatni AA et al. Expression of tumor
necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor,
fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues
and in tissues affected by periodontitis. J Periodontal Res 2010; 45:
564–573.
83. Inta I, Frauenknecht K, Dorr H et al. Induction of the cytokine TWEAK
and its receptor Fn14 in ischemic stroke. J Neurol Sci 2008; 275:
117–120.
84. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B et al. TWEAK and
Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci
2007; 12: 3648–3655.
85. Chicheportiche Y, Fossati-Jimack L, Moll S et al. Down-regulated
expression of TWEAK mRNA in acute and chronic inflammatory
pathologies. Biochem Biophys Res Commun 2000; 279: 162–165.
86. Schwartz N, Su L, Burkly LC et al. Urinary TWEAK and the activity
of lupus nephritis. J Autoimmun 2006; 27: 242–250.
87. Liu ZC, Zhou QL, Li XZ et al. Elevation of human tumor necrosis
factor-like weak inducer of apoptosis in peripheral blood mononuclear
cells is correlated with disease activity and lupus nephritis in
patients with systemic lupus erythematosus. Cytokine 2011; 53:
295–300.
88. Zhao Z, Burkly LC, Campbell S et al. TWEAK/Fn14 interactions are
instrumental in the pathogenesis of nephritis in the chronic graft-
versus-host model of systemic lupus erythematosus. J Immunol 2007;
179: 7949–7958.
89. Monrad SU, Killen PD, Anderson MR et al. The role of aldosterone
blockade in murine lupus nephritis. Arthritis Res Ther 2008; 10: R5.
90. Cleary CM, Moreno JA, Fernandez B et al. Glomerular haematuria,
renal interstitial haemorrhage and acute kidney injury. Nephrol Dial
Transplant 2010; 25: 4103–4106.
91. Metz-Kurschel U, Kurschel E, Wagner K et al. Folate nephropathy
occurring during cytotoxic chemotherapy with high-dose folinic acid
and 5-fluorouracil. Ren Fail 1990; 12: 93–97.
92. Ortega A, Ramila D, Ardura JA et al. Role of parathyroid hormone-related
protein in tubulointerstitial apoptosis and fibrosis after folic acid-
induced nephrotoxicity. J Am Soc Nephrol 2006; 17: 1594–1603.
93. de Haij S, Woltman AM, Bakker AC et al. Production of inflammatory
mediators by renal epithelial cells is insensitive to glucocorticoids.
Br J Pharmacol 2002; 137: 197–204.
94. Nakashima Y, Plump AS, Raines EW et al. ApoE-deficient mice develop
lesions of all phases of atherosclerosis throughout the arterial tree.
Arterioscler Thromb 1994; 14: 133–140.
95. Buzello M, Haas CS, Hauptmann F et al. No aggravation of renal injury
in apolipoprotein E knockout mice (ApoE(/)) after subtotal
nephrectomy. Nephrol Dial Transplant 2004; 19: 566–573.
96. Bruneval P, Bariety J, Belair MF et al. Mesangial expansion associated
with glomerular endothelial cell activation and macrophage recruitment
is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant
2002; 17: 2099–2107.
97. Wen M, Segerer S, Dantas M et al. Renal injury in apolipoprotein
E-deficient mice. Lab Invest 2002; 82: 999–1006.
98. Sun J, Langer WJ, Devish K et al. Compensatory kidney growth in
estrogen receptor-alpha null mice. Am J Physiol Renal Physiol 2006; 290:
F319–F323.
99. Flyvbjerg A, Bennett WF, Rasch R et al. Compensatory renal growth
in uninephrectomized adult mice is growth hormone dependent.
Kidney Int 1999; 56: 2048–2054.
100. Tanabe K, Bonilla I, Winkles JA et al. Fibroblast growth factor-inducible-
14 is induced in axotomized neurons and promotes neurite outgrowth.
J Neurosci 2003; 23: 9675–9686.
101. Kamata K, Kamijo S, Nakajima A et al. Involvement of TNF-like weak
inducer of apoptosis in the pathogenesis of collagen-induced arthritis.
J Immunol 2006; 177: 6433–6439.
102. Moreno JA, Dejouvencel T, Labreuche J et al. Peripheral artery disease is
associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb
Vasc Biol 2010; 30: 1253–1262.
103. Jelic-Ivanovic Z, Bujisic N, Spasic S et al. Circulating sTWEAK improves
the prediction of coronary artery disease. Clin Biochem 2009; 42:
1381–1386.
104. Chorianopoulos E, Rosenberg M, Zugck C et al. Decreased soluble
TWEAK levels predict an adverse prognosis in patients with chronic
stable heart failure. Eur J Heart Fail 2009; 11: 1050–1056.
105. Richter B, Rychli K, Hohensinner PJ et al. Differences in the predictive
value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
in advanced ischemic and non-ischemic heart failure. Atherosclerosis
2010; 213: 545–548.
106. Martin-Ventura JL, Lindholt JS, Moreno JA et al. Soluble TWEAK plasma
levels predict expansion of human abdominal aortic aneurysms.
Atherosclerosis 2011; 214: 486–489.
107. Carrero JJ, Ortiz A, Qureshi AR et al. Additive effects of soluble TWEAK
and inflammation on mortality in hemodialysis patients. Clin J Am Soc
Nephrol 2009; 4: 110–118.
108. Yilmaz MI, Carrero JJ, Ortiz A et al. Soluble TWEAK plasma levels as a
novel biomarker of endothelial function in patients with chronic kidney
disease. Clin J Am Soc Nephrol 2009; 4: 1716–1723.
109. Kralisch S, Ziegelmeier M, Bachmann A et al. Serum levels of the
atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and
end-stage renal disease. Atherosclerosis 2008; 199: 440–444.
110. Yilmaz MI, Carrero JJ, Martin-Ventura JL et al. Combined therapy with
renin-angiotensin system and calcium channel blockers in type 2
diabetic hypertensive patients with proteinuria: effects on soluble
TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5:
1174–1181.
111. Nagasawa M, Yi Z, Imashuku S et al. Soluble TWEAK is markedly elevated
in hemophagocytic lymphohistiocytosis. Am J Hematol 2008; 83:
222–225.
112. Williams SA, Martin SK, Vincent C et al. Circulating levels of TWEAK
correlate with bone erosion in multiple myeloma patients. Br J Haematol
2010; 150: 373–376.
113. ElGendi SS, El-Sherif WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/
CD8 ratio in systemic lupus erythematosus and their relations to disease
activity and renal involvement. Egypt J Immunol 2009; 16: 135–148.
114. Chorianopoulos E, Jarr K, Steen H et al. Soluble TWEAK is markedly
upregulated in patients with ST-elevation myocardial infarction and
related to an adverse short-term outcome. Atherosclerosis 2010; 211:
322–326.
115. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract
Res Clin Rheumatol 2005; 19: 785–798.
116. Schwartz N, Rubinstein T, Burkly LC et al. Urinary TWEAK as a biomarker
of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:
R143.
718 Kidney International (2011) 80, 708–718
rev iew AB Sanz et al.: TWEAK, a multifunctional cytokine in kidney injury
